Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

The positive outlook for uniQure NV is supported by significant advancements in its gene therapy pipeline, particularly with AMT-130 for Huntington's disease and AMT-191 for Fabry disease, which demonstrates strong biological proof-of-concept and moves towards dose optimization. The company has shown strategic financial management, reflected in the increase in SG&A expenses, indicating active investment in growth, while also maintaining a balance sheet that allows for strategic flexibility. Additionally, the collaborations and ongoing clinical trials provide a diversified platform that enhances resilience and reduces risks associated with regulatory changes, reinforcing investor confidence in uniQure's innovative therapies and potential future success.

Bears say

uniQure NV faces significant financial challenges as it remains a clinical stage company with no revenue-generating products, resulting in ongoing losses since its inception. The company is also threatened by intense market competition from both existing and emerging therapies that target similar indications, which can adversely affect its market penetration and pricing strategies. Additionally, potential delays in clinical development, regulatory approvals, or commercialization timelines could lead to prolonged development periods and increased operational costs, further straining the company’s financial resources.

uniQure (QURE) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 11 analysts, uniQure (QURE) has a Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.